Showing results (31-40 of 318) with videos related to
Sort By:
Pageof 32
Cancers|May 28, 2019
STAT3: A Promising Therapeutic Target in Multiple MyelomaPhyllis S Y Chong, Wee-Joo Chng, Sanjay de MelRNA Biology|January 5, 2019
Towards understanding of PRC2 binding to RNAJunli Yan, Bibek Dutta, Yan Ting Hee, et al.Trends in Pharmacological Sciences|October 31, 2019
Comprehensive Analysis of ERK1/2 Substrates for Potential Combination ImmunotherapiesLei Yang, Liangzhen Zheng, Wee Joo Chng, et al.Current Hematologic Malignancy Reports|February 18, 2016
Risk Stratification in Multiple MyelomaMelissa Gaik-Ming Ooi, Sanjay de Mel, Wee Joo ChngOncotarget|August 31, 2018
LEE011 and ruxolitinib: a synergistic drug combination for natural killer/T-cell lymphoma (NKTCL)Yan Ting Hee, Junli Yan, Dean Nizetic, et al.Proceedings of the National Academy of Sciences of the United States of America|December 3, 2016
Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomasYinghui Li, Hui Shan Cheng, Wee Joo Chng, et al.Journal of Clinical Pathology|February 18, 2018
Identification of novel fusion transcripts in multiple myelomaMingxuan Lin, Peak Ling Lee, Lily Chiu, et al.Discover Oncology|August 25, 2025
Targeting the CD47-SIRPalpha checkpoint in multiple myelomaTao Ming Sim, Wee Joo Chng, Haiyan Liu, et al.Oncotarget|December 17, 2017
Tumor-derived exosomes in colorectal cancer progression and their clinical applicationsJianbiao Zhou, Xiao-Lan Li, Zhi-Rong Chen, et al.Cancers|April 23, 2022
Metabolic Vulnerabilities in Multiple MyelomaJulia S L Lim, Phyllis S Y Chong, Wee-Joo ChngPageof 32